SCHEMBL7447200

SCHEMBL7447200

Brc1ccccc1CN1CCCC1

nearest known ligand 0.72

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A13 Q16696 1/20 0.70
ALDH1A1 P00352 5/20 0.68
TSHR P16473 3/20 0.68
RECQL P46063 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
ATM Q13315 1/20 0.58
KDM4E B2RXH2 3/20 0.57
LMNA P02545 1/20 0.57
FAAH O00519 1/20 0.53
HPGD P15428 1/20 0.52
CHRNA7 P36544 1/20 0.51
HTR6 P50406 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
KCNH2 Q12809 1/20 0.50
POLB P06746 1/20 0.50
MPO P05164 1/20 0.48
GFER P55789 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18356563 0.98 ALDH1A1 (0.71) CYP2A13ALDH1A1TSHRRECQLL3MBTL1
SCHEMBL6818375 0.96 ALDH1A1 (0.69) CYP2A13ALDH1A1TSHRRECQLL3MBTL1
SCHEMBL11822769 0.84 CYP2A13 (0.53) CYP2A13ALDH1A1TSHRRECQLL3MBTL1
SCHEMBL11196594 0.84 ALDH1A1 (0.69) ALDH1A1KDM4ELMNACHRNA7POLB
SCHEMBL2931838 0.82 HTR6 (0.69) CYP2A13ALDH1A1TSHRRECQLL3MBTL1
SCHEMBL2925269 0.82 CYP2A13 (0.64) CYP2A13ALDH1A1TSHRRECQLL3MBTL1
SCHEMBL4100083 0.82 CYP2A13 (1.00) CYP2A13ALDH1A1TSHRRECQLL3MBTL1
SCHEMBL4764209 0.82 CYP2A13 (0.64) CYP2A13ALDH1A1TSHRRECQLL3MBTL1
SCHEMBL11194277 0.82 ALDH1A1 (0.73) ALDH1A1TSHRRECQLL3MBTL1KDM4E
SCHEMBL1497101 0.81 CYP2A13 (0.62) CYP2A13ALDH1A1TSHRRECQLL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170002016-A1 AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2017-01-05 US disclosed
US-20170002016-A1 AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2017-01-05 US disclosed
EP-0863755-A4 ANTITHROMBOTIC DIAMINES LILLY CO ELI (US) 1999-01-20 EP disclosed
EP-0863755-A1 ANTITHROMBOTIC DIAMINES ELI LILLY AND COMPANY (US) 1998-09-16 EP disclosed
WO-1997025033-A1 ANTITHROMBOTIC DIAMINES ELI LILLY AND COMPANY (US) 1997-07-17 WO disclosed
US-5321138-A Phenyl selenide derivatives THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1994-06-14 US disclosed
US-5128365-A Reduction of hydrogen peroxide, treatment of cataracts THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1992-07-07 US disclosed
WO-1991001125-A2 COMPOUNDS HAVING GLUTATHIONE PEROXIDASE ACTIVITY AND USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1991-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170002016-A1 AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPM5 CYP2A13 2677/4885ALDH1A1 2024/4885TSHR 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.